MariMed Inc.

What they do

MariMed develops, owns and manages state-licensed cannabis cultivation, production and dispensing facilities for medicinal and adult-use cannabis. It sells its branded flower, concentrates, edibles and precision-dosed products both wholesale to dispensaries operated by other license holders and through its own Thrive Dispensary retail locations. It also generates limited, non-material revenue from brand licensing, management fees and real estate income.

Revenue drivers

• Wholesale branded products — Products sold to hundreds of dispensaries run by other license holders; management reported wholesale revenue rose 6% sequentially in Q2 2026.
• Retail dispensaries — Company-owned Thrive Dispensary locations selling both MariMed brands and third-party products; management reported retail revenue rose 7% sequentially in Q2 2026.
• Branded product portfolio — Betty's Eddies fruit chews and Vibations drink mix are named as leading brands in Massachusetts, Maryland, Illinois and Delaware; these drive the wholesale mix.
• Licensing, management fees and real estate — Brand licensing in select domestic markets plus management and real estate income, which the company states are not material to consolidated results.

Recent performance

Second quarter 2026 revenue was $41.9 million, up from $39.5 million in Q2 2025 and the highest quarterly revenue in company history. GAAP gross margin was 39% versus 40% a year earlier, and GAAP net loss widened to $3.6 million from $1.4 million. Non-GAAP Adjusted EBITDA was $3.9 million (9% margin), down from $4.8 million (12% margin) in the prior-year quarter. First half 2026 revenue was $81.4 million with a GAAP net loss of $7.3 million. Full-year 2025 revenue was $159.8 million with a net loss of $14.5 million.

Strategy

The company's stated plan is called "Expand the Brand," aimed at becoming a leading cannabis consumer packaged goods company owning top-selling national brands. Priorities include strengthening cultivation and processing for supply consistency, launching new products and formulations, broadening distribution in existing markets, and entering new markets through capital-light brand licensing. Management says it will continue investing in product innovation and depth in existing states. It also cites thoughtful capital allocation and a healthy balance sheet as part of the model.

Risks

• Federal illegality — Cannabis remains a Schedule I controlled substance under the CSA, and MariMed's operations depend on compliance with state and local law in each jurisdiction.
• Rescheduling uncertainty — DEA review of the HHS Schedule III recommendation and executive-branch direction on rescheduling remain unresolved, leaving federal tax and banking conditions uncertain.
• Sustained net losses — The company reported net losses of $16.0 million in 2023, $12.5 million in 2024 and $14.5 million in 2025, with a $3.6 million GAAP net loss in Q2 2026.
• Leverage and liquidity — At June 30, 2026, total liabilities were $147.1 million against $197.2 million of assets and $8.4 million of cash, including $82.7 million of long-term debt.

Outlook

Management said it will build on Q2 2026 results by continuing the Expand the Brand strategy, investing in product innovation and broadening depth in existing states while pursuing new markets through capital-light brand licensing. It flagged federal rescheduling of medical cannabis, potential recreational rescheduling, 280E tax relief and banking reform as catalysts that could improve the operating environment. No numeric guidance was provided in the excerpts.